Multistrain Probiotics Against Bacterial Vaginosis
Launched by INSTITUT ALLERGOSAN PHARMA GMBH · Mar 20, 2025
Trial Information
Current as of May 09, 2025
Terminated
Keywords
ClinConnect Summary
If bacterial vaginosis (BV) is detected using the Nugent score (= gold standard for studies) and Amsel criteria, the patient in question is eligible for the study, provided the following additional criteria are met:
* \>16 years of age
* Proof of BV using the Nugent Score (≥ 6)
* Written informed consent for the study (the document is available in printed form in the study folder). Additional parental information is available for underage patients
Please also note the following exclusion criteria:
* Consumption of other probiotics within the last 4 weeks
* Pregnancy, breastfeeding
* Infe...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 16 years
- • Proof of BV using the Nugent Score (\> 6)
- • Written informed consent for the study (the document is available in printed form in the study folder).
- • Additional parental information is available for underage patients
- Exclusion Criteria:
- • Consumption of other probiotics within the last 4 weeks
- • Pregnancy, breastfeeding
- • Infections of the urogenital tract
- • Participation in another study
- • Infection with other vaginal germs or vaginal mycosis
- • Hepatitis B, C or HIV infection
- • Planned hospitalisation during the intervention period
About Institut Allergosan Pharma Gmbh
Institut Allergosan Pharma GmbH is a leading clinical research organization specializing in the development of innovative therapeutic solutions for allergic and autoimmune diseases. With a commitment to advancing healthcare, the company focuses on conducting rigorous clinical trials that adhere to the highest scientific and ethical standards. Leveraging a team of experienced professionals and state-of-the-art technology, Institut Allergosan Pharma GmbH aims to bring novel treatments to market, improving patient outcomes and enhancing quality of life for individuals affected by chronic conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vienna, , Austria
Patients applied
Trial Officials
Doris Maria Gruber, Univ. Prof. Dr.
Principal Investigator
Wahlarztordination Wien, Lainzerstrasse 147, A-1130 Wien
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported